This page shows Earth Life Scien (CLTS) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 8 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Financial Health Signals
Based on FY2021 annual data, averaged across the last 3 years for performance metrics (most-recent year weighted highest). How this score is calculated →
Health score ≠ stock price. This rates the quality of Earth Life Scien's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Earth Life Scien carries a low D/E ratio of 0.09, meaning only $0.09 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 100/100, indicating a strong balance sheet with room for future borrowing.
Earth Life Scien generates a -39.1% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 0/100.
Earth Life Scien passes 1 of 9 financial strength tests. 1 of 3 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution).
For every $1 of reported earnings, Earth Life Scien generates $0.01 in operating cash flow (-$16K OCF vs -$1.6M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Earth Life Scien reported -$1.6M in net income in fiscal year 2021.
Cash & Balance Sheet
Earth Life Scien had 961M shares outstanding in fiscal year 2021. This represents an increase of 106.7% from the prior year.
Margins & Returns
Earth Life Scien's ROE was -39.1% in fiscal year 2021, measuring profit generated per dollar of shareholder equity.
Capital Allocation
CLTS Income Statement
| Metric | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 | Q4'20 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| R&D Expenses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| SG&A Expenses | $11K+819.8% | $1K-45.5% | $2K | N/A | $9K+193.7% | $3K+3.0% | $3K | N/A |
| Operating Income | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Interest Expense | $2K-49.0% | $5K-10.0% | $5K | N/A | $6K+1.3% | $6K+11.7% | $5K | N/A |
| Income Tax | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income | -$21K+93.5% | -$322K-799.5% | -$36K | N/A | -$22K-103.8% | -$11K | N/A | N/A |
| EPS (Diluted) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CLTS Balance Sheet
| Metric | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 | Q4'20 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $4.4M0.0% | $4.4M0.0% | $4.4M0.0% | $4.4M+2400.9% | $177K-1.7% | $180K0.0% | $180K+2.3% | $176K |
| Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | $4K-97.7% | $176K |
| Cash & Equivalents | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $411K+5.4% | $390K-4.6% | $409K+9.6% | $373K-0.5% | $375K+5.5% | $355K+3.2% | $344K-8.9% | $378K |
| Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | $344K-8.9% | $378K |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $4.0M-0.5% | $4.0M+0.5% | $4.0M-0.9% | $4.1M+2150.4% | -$198K-12.8% | -$175K-6.7% | -$164K+18.6% | -$202K |
| Retained Earnings | -$19.1M-0.1% | -$19.1M-1.7% | -$18.7M-0.2% | -$18.7M-0.1% | -$18.7M-0.1% | -$18.7M-0.1% | -$18.7M-9.0% | -$17.1M |
CLTS Cash Flow Statement
| Metric | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 | Q4'20 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $0+100.0% | -$4K-404.1% | -$800-126.6% | $3K | $0+100.0% | -$6K+53.4% | -$13K+37.7% | -$21K |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Investing Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Financing Cash Flow | $0-100.0% | $4K+404.1% | $800 | $0+100.0% | -$3K-150.0% | $6K-53.4% | $13K-37.7% | $21K |
| Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
CLTS Financial Ratios
| Metric | Q3'22 | Q2'22 | Q1'22 | Q4'21 | Q3'21 | Q2'21 | Q1'21 | Q4'20 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | -0.5%+7.5pp | -8.0%-7.1pp | -0.9% | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | -0.5%+6.8pp | -7.3%-6.5pp | -0.8% | N/A | -12.7%-6.5pp | -6.1% | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | 0.01-0.5 | 0.47 |
| Debt-to-Equity | 0.100.0 | 0.100.0 | 0.100.0 | 0.09+2.0 | -1.90+0.1 | -2.03+0.1 | -2.10-0.2 | -1.87 |
| FCF Margin | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
Is Earth Life Scien profitable?
No, Earth Life Scien (CLTS) reported a net income of -$1.6M in fiscal year 2021.
What is Earth Life Scien's return on equity (ROE)?
Earth Life Scien (CLTS) has a return on equity of -39.1% for fiscal year 2021, measuring how efficiently the company generates profit from shareholder equity.
What is Earth Life Scien's operating cash flow?
Earth Life Scien (CLTS) generated -$16K in operating cash flow during fiscal year 2021, representing cash generated from core business activities.
What are Earth Life Scien's total assets?
Earth Life Scien (CLTS) had $4.4M in total assets as of fiscal year 2021, including both current and long-term assets.
What is Earth Life Scien's debt-to-equity ratio?
Earth Life Scien (CLTS) had a debt-to-equity ratio of 0.09 as of fiscal year 2021, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Earth Life Scien's return on assets (ROA)?
Earth Life Scien (CLTS) had a return on assets of -35.8% for fiscal year 2021, measuring how efficiently the company uses its assets to generate profit.
What is Earth Life Scien's Piotroski F-Score?
Earth Life Scien (CLTS) has a Piotroski F-Score of 1 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Earth Life Scien's earnings high quality?
Earth Life Scien (CLTS) has an earnings quality ratio of 0.01x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Earth Life Scien?
Earth Life Scien (CLTS) scores 17 out of 100 on our Financial Profile, indicating weak overall financial health. This composite score evaluates six dimensions: profitability (operating margin), revenue growth, leverage (debt-to-equity), liquidity (current ratio), cash flow quality (free cash flow margin), and shareholder returns (return on equity). Each dimension is normalized against standard financial benchmarks. Learn more in our complete guide to financial health indicators.